Camp4 Therapeutics (CAMP) Company Report

Camp4 is advancing CMP002 for Syngap1-related disorders, a haploinsufficiency affecting over 10,000 patients in the U.S. and globally. Preclinical data demonstrated full protein recovery in patient cells and reversal of cognitive issues in humanized mice.
The company initiated GLP-tox studies for CMP002 in Q3 2025 and anticipates entering the clinic as early as H2 2026.
Camp4 reported $75 million in cash at the end of Q3 2025, with an additional $50 million expected upon CTA or IND acceptance for CMP002. This funding is projected to comfortably last into 2027, covering the period until potential clinical proof-of-concept in a Phase 1/2 study for Syngap patients.
Camp4 is pausing investment in its CMP001 program for urea cycle disorders and is actively seeking a partner.

4 days ago

Camp4 Provides Update on Lead Program CMP002, Financial Runway, and Partnership Strategy

CAMP

New Projects/Investments

Guidance Update

Camp4 is advancing its platform of regulatory RNA (regRNA) medicines, which use antisense oligonucleotides to upregulate gene expression, primarily targeting haploinsufficiencies within the central nervous system (CNS).
The company's lead program, CMP002 for Syngap1-related disorders, initiated GLP-tox studies in Q3 2025 and is projected to enter the clinic as early as H2 2026. Syngap1-related disorders are estimated to affect over 10,000 patients in the U.S. and globally.
Camp4 reported $75 million in cash at the end of Q3 (2025) and anticipates an additional $50 million upon CTA/IND acceptance for CMP002, which is expected to provide a cash runway into 2027 and through potential clinical proof of concept for CMP002.
The company is actively seeking a partner for its CMP001 program for urea cycle disorders to prioritize its genetic epilepsy pipeline and has an existing two-target discovery deal with BioMarin for targets outside the liver and CNS.

4 days ago

CAMP4 Therapeutics Reports Q3 2025 Financial Results and Strategic Program Updates

CAMP

Earnings

New Projects/Investments

M&A

CAMP4 Therapeutics reported a net loss of $15.1 million for the third quarter ended September 30, 2025, and held $75.3 million in cash, cash equivalents, and marketable securities as of that date.
The company strengthened its balance sheet by securing an initial $50 million from a private placement, with potential proceeds up to $100 million, which is expected to extend its cash runway into 2027.
CAMP4 initiated GLP toxicology studies for CMP-002, its lead program for SYNGAP1-related disorders, with a Phase 1/2 clinical trial anticipated to begin as early as H2 2026.
Following favorable Phase 1 trial results for CMP-001, the company made a strategic decision to pursue partnerships for its continued development in urea cycle disorders.

Nov 6, 2025, 9:08 PM

CAMP's CORRIDOR Advances AI Operations Manager to Production

CAMP

Product Launch

CORRIDOR, a product line of CAMP Systems, has deployed its AI Operations Manager with ACI Jet following a successful pilot program.
The AI Operations Manager applies predictive intelligence to modernize maintenance planning and execution, aiming to enhance accuracy, efficiency, and profitability for service centers and MROs.
Early deployments have demonstrated measurable results, including up to 10% faster sales cycles, a 50% reduction in unpaid work, and cost savings of up to 20% through improved mechanic efficiency and optimized material planning.
ACI Jet confirmed that this technology is already creating a measurable impact across their operations by anticipating labor and parts needs, reducing variability, and improving turnaround times.

Oct 15, 2025, 3:00 PM

CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

CAMP

New Projects/Investments

CAMP4 Therapeutics Corporation has initiated GLP toxicology studies for its lead product candidate, CMP-SYNGAP-01, as of October 1, 2025.
These studies are a critical step towards a planned clinical trial application, which could enable the initiation of a first-in-human Phase 1/2 clinical trial for SYNGAP1-related disorders as early as the second half of 2026.
CMP-SYNGAP-01 is an investigational therapeutic designed to upregulate SYNGAP1 gene expression to restore SYNGAP protein levels, addressing SYNGAP1-related disorders for which there are no FDA-approved disease-modifying therapies.
Preclinical studies have demonstrated robust activity for CMP-SYNGAP-01, including restoring SYNGAP1 protein levels in a mouse model and increasing SYNGAP1 protein in non-human primate brain regions.